Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial.
Ruan DY, Liu FR, Wei XL, Luo SX, Zhuang ZX, Wang ZN, Liu FN, Zhang YQ, Yang JW, Chen ZD, Wang YS, Wang JY, Liang XH, Wu XJ, Zheng YL, Liu J, Shi X, Kumar R, Liu W, Chen B, Zhang DS, Xu RH.
Ruan DY, et al. Among authors: wu xj.
Lancet Oncol. 2025 Jan 6:S1470-2045(24)00636-3. doi: 10.1016/S1470-2045(24)00636-3. Online ahead of print.
Lancet Oncol. 2025.
PMID: 39788133